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Abstract
The double-stranded RNA-activated protein kinase R (PKR) is a key regulator of the innate immune response. Activation of
PKR during viral infection culminates in phosphorylation of the a subunit of the eukaryotic translation initiation factor 2
(eIF2a) to inhibit protein translation. A broad range of regulatory functions has also been attributed to PKR. However, as few
additional PKR substrates have been identified, the mechanisms remain unclear. Here, PKR is shown to interact with an
essential RNA helicase, RHA. Moreover, RHA is identified as a substrate for PKR, with phosphorylation perturbing the
association of the helicase with double-stranded RNA (dsRNA). Through this mechanism, PKR can modulate transcription, as
revealed by its ability to prevent the capacity of RHA to catalyze transactivating response (TAR)–mediated type 1 human
immunodeficiency virus (HIV-1) gene regulation. Consequently, HIV-1 virions packaged in cells also expressing the decoy
RHA peptides subsequently had enhanced infectivity. The data demonstrate interplay between key components of dsRNA
metabolism, both connecting RHA to an important component of innate immunity and delineating an unanticipated role
for PKR in RNA metabolism.
Citation: Sadler AJ, Latchoumanin O, Hawkes D, Mak J, Williams BRG (2009) An Antiviral Response Directed by PKR Phosphorylation of the RNA Helicase A. PLoS
Pathog 5(2): e1000311. doi:10.1371/journal.ppat.1000311
Editor: Michael Gale Jr., University of Washington, United States of America
Received July 9, 2008; Accepted January 23, 2009; Published February 20, 2009
Copyright:  2009 Sadler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by NIH grant R01 AI034039-14.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: anthony.sadler@med.monash.edu.au
Introduction
The primary detection of viral infection is by the host innate
immune system, with the recognition of viral double-stranded
RNA (dsRNA) a crucial early function. Responses to dsRNA are
mediated by several protein receptors that recognize this
pathogen-associated molecular pattern (PAMP). Most important
of these receptors are the Toll-like receptor-3 (TLR3), two caspase
recruitment domain (CARD)-containing helicases, retinoic acid
inducible gene-I (RIG-I) and the related IFN inducible helicase-I
(IFIH-I), and the protein kinase R (PKR). These dsRNA receptors
are spatially separated within the cell to respond to either intra- or
extra-cellular dsRNA. Moreover, the outcome of the ensuing
antiviral response triggered by each receptor differs between cell
compartments [1]. Consequently, a full contingent of pattern
recognition receptors is required for immune competence. TLR3
is located on the cell surface or in the endosome compartment, and
upon sensing dsRNA recruits the cytoplasmic adaptor Toll/IL-1R
(TIR) domain-containing adaptor-inducing IFNb (TRIF), via
shared TIR homologous regions to mediate antiviral responses
[2–4]. Adaptor signaling leads to IFN regulatory factor (IRF)3 and
IRF7 activation and type-I IFN production [5,6]. RIG-I and
IFIH-I are cytoplasmic receptors which sense dsRNA and
subsequently transmit a signal via helicase and CARD domains,
respectfully. Activated RIG-I/IFIH-I associate with a mitochon-
drial anchored CARD adaptor, IPS-1 (also called MAVS, Cardif,
or VISA), to activate NFkB and IRF3 and induce IFNb [7–10].
Alternatively, dsRNA-binding at the amino terminus of PKR
activates the kinase, resulting in the phosphorylation of the a
subunit of the eukaryotic translation initiation factor 2 (eIF2a) and
inhibition of protein translation within infected cells [11]. In
addition, PKR evokes cellular responses by modulating cell-
signaling pathways. The mechanisms by which PKR functions as a
signaling molecule have not been fully delineated. However, PKR
has been shown to mediate the responses to other PAMPs,
including bacterial LPS, as well as stress stimuli such as IFNc,
TNFa, mitomycin C, and serum deprivation by inducing
degradation of inhibitor kB (IkB), IRF1 expression, indirectly
mediating STAT1 phosphorylation, and triggering apoptotic
pathways [12,13]. These broad responses are not reconciled with
a narrow mechanism involving translational control through
eIF2a. However, few other PKR substrates are known that
account for these cellular responses.
PKR has two domains, a C-terminal catalytic domain and an
N-terminal regulatory domain. The N-terminus encodes tandem
RNA-binding motifs (RBMs). The RBMs not only recognize
dsRNA to activate PKR, but also serve as an autoinhibitory
domain, as well as mediating dimerization to form the fully active
kinase molecule. These observations suggest an additional function
for RBMs as protein–protein interaction domains. Support for this
comes from other proteins identified to interact with PKR. The
protein activator of PKR (PACT) encodes three RBMs, and the
structurally similar transactivating response (TAR)-RNA binding
protein (TARBP) interacts with PKR to, conversely, inhibit the
kinase. That RBMs might mediate interactions between proteins,
particularly other RBMs, highlights an emerging concept that has
consequence for coordinating the dsRNA response in cells. In this
way the RBM might be considered as a signaling domain,
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analogous to the TIR domain of TLRs or the CARD domain of
RIG-I and IFIH-I to mediate homo- or heterotypic protein
interactions.
Here, we identify an interaction between PKR and another
protein encoding RBMs, the RNA helicase A (RHA). RHA is an
essential DEAH-box protein that exhibits both RNA and DNA
helicase activity [14]. The association is demonstrated to be via the
helicase RBMs. Importantly, biochemical analysis shows RHA is a
substrate for PKR, and demonstrates that phosphorylation
modulates the helicase association with its nucleic acid substrate.
The consequences of these observations are examined in relation
to RHA’s previously established role in retroviral infection. PKR is
shown to mediate transcriptional activity and HIV-1 infectivity via
phosphorylation of RHA. These findings identify a novel function
for PKR, delineating a new cell signaling pathway to target in anti-
HIV-1 therapy, and highlighting a process by which proteins that
respond to dsRNA may be coordinated.
Results
PKR Associates with RHA In Vivo
To detect proteins interacting with PKR, the kinase was
immunoprecipitated from isogenic, pkr-null mouse embryonic
fibroblasts (MEFs) either silenced or expressing human PKR from
the native promoter elements at physiologic levels. The cells were
stimulated with the synthetic, dsRNA mimic polyinosinic-poly-
cytidylic acid (pIC) to activate the kinase. A 140 kDa protein band
was coimmunoprecipitated with a monoclonal anti-PKR antibody
(Figure 1A). Mass spectrometric analysis of this protein identified
11 different peptide sequences that matched the amino acid
sequence of murine RHA (Table 1).
Immunoprecipitation and Western blot analysis were conducted
to verify this protein association. The protein interaction was
confirmed in MEFs isolated from wild-type and pkr null mice by
performing the reciprocal immunoprecipitation, using a anti-RHA
monoclonal antibody, then detecting coimmunoprecipited PKR
(Figure 1B). This experiment was repeated in the rescued pkr null
MEFs expressing the human kinase, with and without stimulation
of the cells with pIC to activate PKR. Coimmunoprecipitation of
PKR and RHA only occurred with pIC treatment, demonstrating
that the protein interaction is dependent upon activation of the
kinase (Figure 1C). Notably, pIC appears to modulate the
conformation of RHA as the protein is not immunoprecipitated
by its own antibody from untreated cell lysates. This supports a
previous suggestion that the constitutively expressed helicase is
maintained in an inactive conformation, likely via the protein’s
RBM, under basal conditions [15].
PKR Associates Directly with the N-Terminus of RHA
In vitro binding studies were conducted to map the association
between PKR and RHA. Six different glutathione-S-transferase
(GST) fusion constructs, together spanning the full helicase, were
used in a GST-pull down experiment to determine which region of
RHA associated with PKR. This experiment showed PKR
associated exclusively with the first 263 amino acids of RHA that
encodes its two RBMs (Figure 2A). Since the first RBM, encoded
between amino acids 1 to 79, did not associate with PKR, it
appears that the second RBM is the interacting region, or both
RBMs are required. Efforts to map the region of PKR that
interacts with RHA were inconclusive. Binding assays with the
isolated RBM or kinase domains of PKR showed the N-terminal
RBMs interacted specifically with RHA. However, the truncated
C-terminus of PKR bound non-specifically to the control (beads
only) in the assay conditions. Subsequent analysis suggests the
RBM of RHA interacts with both C- and N-terminal domains of
PKR (see below).
RHA encodes several domains that bind dsRNA, located in the
helicase domain, the C-terminal RGG box, as well as the two
RBMs at the N-terminus, that did not associate with PKR. This
implies that the PKR-RHA interaction is direct and not through
mutual association with dsRNA. Moreover, it has been established
that PKR dissociates from dsRNA upon activation, autopho-
sphorylation and dimerization [16]. Consequently, an indirect
association between PKR and RHA, bridged by dsRNA, is
unlikely. However, to unequivocally establish that the two proteins
interact directly, several experiments were conducted.
First the ability of a 16 bp dsRNA molecule to block the
association between in vitro synthesized PKR and the N-terminal
263 amino acid GST-fusion construct of RHA was measured. This
short dsRNA, although able to bind to a single RBM, is not long
enough to interact with two RBMs from separate proteins [17].
The results (Figure 2B) showed that the 16 bp dsRNA did not
perturb the association between PKR and RHA, even when
present at considerable molar excess. Next, alternative cell
treatments that did not use pIC to activate PKR were evaluated
and coimmunoprecipitations performed. Accordingly, treatment
of the human monocytic cell line, THP-1, with LPS, demonstrated
to activate PKR [18], induces the association between the kinase
and RHA (Figure 2C). Finally, triggering of PKR with its protein
activator PACT [19] effected association between PKR and RHA.
HEK293T cells were cotransfected with expression constructs for
RHA and wild-type PACT or a mutant (DPACT) that does not
activate PKR and treated with actinomycin-D to stimulate PACT,
then PKR was immunoprecipitated. Figure 2D shows the wild-
type and not the mutant PACT increased the association between
PKR and the helicase. Together these data demonstrate that PKR
interacts directly with the N-terminal region of RHA, and that this
interaction is dependent upon activation of the kinase.
RHA Is a Substrate for PKR
To investigate the possible consequences of this interaction, we
tested whether RHA is a substrate for PKR-mediated phosphor-
Author Summary
Our manuscript explores the immune response to viral
infection by investigating events triggered by the protein
kinase PKR. This sentinel kinase is constitutively expressed
in all cells as an inactive protein that is subsequently
activated by viral RNA produced during an infection. The
active kinase perturbs viral replication by phosphorylating
protein substrates in the cell. In this manuscript we identify
a novel substrate for PKR, an essential helicase, RHA.
Viruses usurp this helicase to replicate their own genome.
We demonstrate that phosphorylation of RHA by PKR
perturbs the ability of the helicase to bind viral RNA.
Correspondingly, PKR prevents the capacity of RHA to
enhance expression of genetic elements encoded by the
human immunodeficiency virus (HIV). Juxtaposed to this,
HIV virions packaged within cells that also express protein
fragments of RHA, demonstrated to interact with PKR as
decoy substrates, have enhanced infectivity. These frag-
ments of RHA occur within a protein domain previously
established to bind RNA but increasingly recognized to
mediate protein–protein interactions. This supports an
emerging role for these protein domains to coordinate the
cell’s response to pathogen-associated RNA. The findings
identify a new cell-signaling pathway important in the
response to viral infection.
Regulation of RHA by PKR
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ylation. An in vitro kinase assay was performed with proteins
coimmunoprecipitated from MEFs using a monoclonal antibody
against PKR. The results (Figure 3A) show RHA bound to PKR at
physiological ratios was phosphorylated by the associated PKR in
a subsequent kinase assay. To measure phosphorylation in vivo
RHA was directly immunoprecipitated with antibodies to RHA,
or coimmunoprecipitated with an anti-PKR antibody from HeLa
cells treated with pIC. The resulting immune complexes were
probed by western blot for phosphorylated residues using anti-
phosphoserine and anti-phosphothreonine antibodies. Figure 3B
shows only the RHA in complex with PKR had detectable
phosphorylated serine and threonine residues. Detection of
phosphorylated RHA specifically associated with the kinase,
strongly suggesting direct phosphorylation of RHA by PKR.
The antibody used to immunoprecipitate RHA in this experiment
(ab2627 from Abcam) was raised against a synthetic peptide
derived from within residues 100 to 200 of human RHA. This is
within the region of RHA demonstrated to associate with PKR
(between residues 80 to 263, Figure 2A). As this antibody and
PKR interacts with the same region of RHA mutual association is
excluded. Consequently, PKR is not coimmunoprecipitated with
this anti-RHA antibody (Figure 3B). This confirms the GST-pull
down experiments and further narrows the region mediating the
interaction between the RHA and PKR.
Phosphorylation of RHA by PKR was confirmed in an in vitro
kinase assay, using purified recombinant PKR and RHA
(Figure 3C). To examine the possible functional consequences of
phosphorylation by PKR we mapped the region of RHA that is
modified. Accordingly, an in vitro kinase assay was conducted with
truncated GST-fusion constructs of RHA and recombinant PKR.
Figure 3D demonstrates that RHA is phosphorylated within the
263 amino acid region previously demonstrated to interact with
PKR. Hence, the RBM of RHA must interact with the catalytic
kinase domain of PKR. This is consistent with previous evidence
showing other RBMs, for instance from PACT, are phosphory-
lated by PKR [20,21].
Figure 1. PKR associates with RHA. (A) A silver-stained, SDS-PAGE gel of electrophoretically separated proteins immunoprecipitated with mouse
monoclonal anti-PKR (IP-PKR) from pkr-null MEFs transformed with a human pkr construct either expressed (+) or silenced (2) and stimulated with
pIC to activate the kinase. Arrows indicate the 68 kDa PKR and an associated 140 kDa protein. (B) A Western blot of proteins immunoprecipitated
using a mouse monoclonal antibody to RHA (IP-RHA) from MEFs isolated form wild-type (+) or pkr-null (2) mice. Coimmunoprecipitated proteins are
detected with rabbit polyclonal antibodies to RHA (upper panel), or murine PKR (lower panel). The levels of RHA expressed in the different cells were
detected in whole cell lysates with the polyclonal anti-RHA antibody (Input). (C) A Western blot of proteins immunoprecipitated using antibodies to
either PKR or RHA from pkr-null MEFs transformed with human PKR either expressed (+) or silenced (2) and differentially treated with pIC.
Coimmunoprecipitated proteins are detected with opposing antibodies for RHA (upper panel) and PKR (lower panel).
doi:10.1371/journal.ppat.1000311.g001
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PKR Perturbs the Association of RHA with RNA
As the N-terminal 263 amino acid region of RHA regulates the
association with dsRNA, it seemed evident that addition of a
negatively charged phosphate group to this region would perturb
RHA’s interaction with dsRNA. To test this hypothesis we
measured the relative affinity of the phosphorylated or unpho-
sphorylated RHA peptide for pIC. The 263 amino acid RHA
peptide was either taken directly from an in vitro synthesis
reaction, or subsequently phosphorylated by PKR in an in vitro
kinase assay following synthesis. Approximately 19% of the total
35S-labeled RHA peptide was recovered in a pIC pull down. In
contrast, none of the phosphorylated RHA peptide, evidenced as a
32P-labeled product, bound pIC (Figure 4). Consequently,
phosphorylation of the RHA peptide by PKR inhibited pIC
binding. Given that phosphorylation perturbs RHA’s association
with its nucleic acid substrate, we would expected PKR should
have a profound effect upon the function of the helicase in vivo.
Figure 2. Activated PKR directly associates with the N-terminus of RHA. (A) An autoradiograph of 35S-labeled PKR, pulled down with
GSTRHA fusion proteins and GST alone. Amino acid end points for the RHA construct are indicated over each lane. (B) An autoradiograph of 35S-
labeled PKR pulled down with a GSTRHA fusion protein encoding amino acid residues 1 to 263 in a competitive reaction with 0, 10, 100, or 1000 fold
excess of a 16 nucleotide dsRNA. (C) A Western blot of proteins immunoprecipitated with a monoclonal antibody to PKR (IP-PKR) from lysates of the
human monocyte THP-I cell line, differentially treated (+/2) with LPS to activate the kinase. Proteins are detected with rabbit anti-RHA (top panel) or
mouse anti-PKR (middle panel). Activation of PKR was confirmed by detection with a rabbit anti-phosphoS51-eIF2a (P-eIF2a; bottom panel). (D) A
Western blot of proteins immunoprecipitated with a monoclonal antibody to PKR (IP-PKR) from lysates of HEK293T transfected with HA-tagged RHA
and PACT or the deletion construct D3PACT and temporally treated with actinomycin-D (mins ActD) to activate PKR. Proteins were detected with a
rabbit anti-HA (RHA; top panel) and mouse anti-PKR antibody (bottom panel).
doi:10.1371/journal.ppat.1000311.g002
Table 1. Mass spectrophotometry sequencing of the PKR-
associated protein
Peptide Sequence Matched RHA Residues
NFLYAWCGK 6–14
DAQSNAAR 56–63
DFVNYLVR 64–71
AENNSEVGASGYGVPGPTWDR 121–141
GANLK 142–146
DYYSRK 147–152
LIQYFQK 185–191
EKIQGEYK 192–199
YTQVGPDHNR 200–209
SFIAEMTIYIK 210–220
LAAQSCALSLVR 237–248
doi:10.1371/journal.ppat.1000311.t001
Regulation of RHA by PKR
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Figure 3. RHA is a substrate for PKR. (A) An autoradiograph (32P; on the left) and Western blot (WB; on the right) showing electrophoretically
separated proteins labeled with 32P by PKR in a kinase assay, or probed with a rabbit anti-RHA antibody, respectively. Proteins were
immunoprecipitated with mouse anti-PKR (IP-PKR) from MEFs expressing human PKR either untreated (2) or treated (+) with pIC. (B) A Western blot
showing electrophoretically separated proteins immunoprecipitated from HeLa cells with anti-PKR (IP-PKR) or anti-RHA (IP-RHA) antibodies, then
probed with anti-phosphoserine (P-Ser) and anti-phosphothreonine (P-Thr). Arrows indicate phosphorylated RHA (P-RHA). Blots were stripped and re-
probed with anti-RHA, or anti-PKR antibodies. Primary antibodies were detected using fluorescent-labeled secondary antibodies. The intensity of the
immune-positive bands from the blot was quantitated, and these values are given at the bottom of each panel as relative arbitrary units. (C) An
autoradiograph of electrophoretically separated proteins labeled with 32P by PKR in an in vitro kinase assay. Arrows indicate autophosphorylated PKR
and phosphorylated RHA, and, as a control, the previously established PKR substrate B56a. PKR activity is induced by treatment with pIC, indicated at
the top of the figure (2/+). (D) An autoradiograph of GSTRHA peptides 32P-labeled by PKR in a kinase assay and electrophoretically separated by SDS-
PAGE gel (upper panel). Amino acid end points for each RHA construct are indicated over each lane. The arrow indicates the phosphorylated RHA
peptide (RHA263). The lower panel shows the Coomassie-stained, SDS-PAGE gel assayed above.
doi:10.1371/journal.ppat.1000311.g003
Regulation of RHA by PKR
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PKR Inhibits RHA Function
Our data supports a model in which PKR regulates RHA by
phosphorylating its RBD thereby decreasing its affinity for RNA.
To determine the in vivo consequence of such regulation, we
investigated PKR’s effect on the reported ability of RHA to
regulate transactivation of the HIV-1 LTR [22]. Accordingly,
transcription of an LTR-EGFP reporter construct was measured
in HEK293T cells in which PKR was depleted by RNA
interference (RNAi). Additional control small interfering RNAs
(siRNAs) against RHA, EGFP, and as an alternative target Lamin
A/C, were cotransfected with the reporter construct to gauge the
RHA dependence of transactivation, the efficacy of RNAi, and to
account for non-specific effects of RNAi, respectively. Since the
HIV-1 LTR RNA has been reported to bind and activate PKR,
no further activating stimulus was used [23]. As depletion of PKR
can increase gene expression by reduced phosphorylation of the
eIF2a translation factor, we delineated specific regulation of LTR-
transactivation by normalizing reporter protein levels to an
internal constitutive Renilla reporter. Western blot analysis
confirmed the specific release of the reporter gene (GFP) relative
to the constitutively expressed GAPDH, and verified appropriate
targeting of each siRNA against PKR, RHA, and as a control GFP
(Figure 5B). The control siRNA to Lamin A/C did not affect
reporter protein levels and is not shown. Depletion of RHA by
siRNA confirms the role of the helicase in LTR-regulated gene
expression (Figure 5A). Significantly, depletion of PKR increased
EGFP expression. The timing of transcriptional release, beginning
at 48 hours, conforms to the anticipated kinetics of the removal of
PKR from the cell, as the kinase has an approximate half-life of
48 hours (B. R. G. Williams, unpublished results).
This effect of PKR on the LTR reporter system was further
tested using three PKR constructs with different catalytic activity.
The requirement for kinase activity for PKR control of RHA-
mediated LTR expression was assessed by comparing the relative
affect of wild-type PKR, and two mutant PKR proteins either;
catalytically active but modified to preclude eIF2a regulation by
substitution of the threonine residue to an alanine at position 487
(T487A) [24], or a kinase dead construct modified by substitution
of a lysine residue to a arginine at position 296 (K296R).
Expression of wild-type PKR reduced RHA-dependent transcrip-
tion of the LTR-EGFP reporter. Conversely, expression of the
catalytically inactive PKR-K296R promotes RHA-dependent
transcription of the reporter (Figure 5C). This construct (K296R)
dimerizes with endogenous PKR, so acts as a dominant negative to
directly inhibit PKR’s regulation of RHA as well as general
protein translation, via wild-type PKR phosphorylation of eIF2a.
The relative contribution of these two mechanisms was explored
by expressing the mutant PKR-T487A that mediates association
with eIF2a. This construct is catalytically active, so will
phosphorylate RHA, but is incapable of regulating translation.
Accordingly, expression of the PKR-T487A showed an interme-
diate affect on the LTR-driven reporter, reflecting direct inhibition
of RHA-mediated induction of the reporter without the wild-type
PKR-mediated regulation of global protein translation (Figure 5C).
The relative contribution of PKR’s direct regulation of RHA
juxtaposed to indirect effect upon translation, demonstrated with
either PKR mutation (K296R or T487A), is made more clear
when the RHA-dependent transcription of the HIV-1 LTR
reporter (EGFP) is normalizing against a constitutive reporter
(Renilla luciferase). This normalization shows the catalytically
inactive PKR-K296R does not affect RHA-mediated transactiva-
tion of the HIV-1 LTR, while the catalytically active PKR-T487A
construct reduces transactivation of the HIV-1 LTR. This data
shows that PKR negatively regulates RHA transactivation of the
retroviral reporter gene by direct phosphorylation control of RHA.
The RHA RBM Increases HIV-1 Infectivity
The preceding data predicts over expression of the RBD of
RHA would perturb PKR function by acting as a decoy substrate.
This prediction is supported by reporter assays in HEK293T cells
that show RHA-regulated LTR expression increases with
increasing amounts of the RHA RBD (Figure 6A). This rescue
effect of RHA’s RBD in the reporter assays should extend to full
viral infection. To test this, we measured the capacity of constructs
that encoded RHA’s RBD, and two truncated constructs, of each
separate RBM within this domain, to enhance HIV-1 infection in
the peripheral blood mononuclear cell line MT-2. As a previous
report had demonstrated that RHA becomes incorporated into the
HIV-1 virion during replication [25], infectious virus was
produced in cells co-expressing the three RHA peptides (RBD,
RBM1, and RBM2, encoding residues 1-263, 1-76, and 169-263,
respectively), and the virions produced were titrated onto the
mononuclear cells. In keeping with the reporter assays, expression
of the RBD significantly increased HIV-1 infectivity. Notably, a
truncation construct from the first RBM (RBM1) that did not
associate with, and was not phosphorylated by, PKR (Figures 2A
and 3D), did not alter HIV-1 infectivity. In contrast, the construct
encoding the second RBM (RBM2), predicted to be the substrate
for PKR, did enhance viral infectivity. In fact, this peptide was
more potent than the domain that encompassed both motifs
(Figure 6B). As these truncated constructs have no helicase activity
and lack other domains demonstrated to enhance retroviral
replication, increased virus infectivity is presumed to be due to the
demonstrated association and inhibition of PKR. However, an
alternative mechanism is conceivable whereby RHA’s RBD might
recruit other cellular factors to enhance viral replication. This was
assessed by measuring the activity of reverse transcriptase in
infections with HIV-1 produced with the control plasmid or each
of the RHA constructs. Importantly, the RHA peptides did not
increase viral replication, as measured by the activity of the viral
reverse transcriptase enzyme (Figure 6C). These experiments
validate the preceding data in a cell infection system, substanti-
ating a consequence of the interaction between PKR and RHA for
the cell’s innate immune response to HIV-1 infection.
Figure 4. PKR phosphorylation perturbs the association of RHA
with RNA. A phosphor image of the recovery of total 35S-labeled RHA
peptide encoding amino acid residues 1 to 263 (top panel) compared to
32P-labeled peptide phosphorylated by PKR in vitro (bottom panel)
pulled down with pIC bound to agarose beads (Ag-pIC) and
electrophoretically separated. The recovery of three replicated radioac-
tively labeled peptides was quantitated as a percentage of the input
extract (Input).
doi:10.1371/journal.ppat.1000311.g004
Regulation of RHA by PKR
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Figure 5. PKR inhibits RHA-mediated transactivation of HIV-1 LTR. (A) A bar graph representing the relative fluorescence levels in transiently
transfected HEK293T cells using a HIV-1 LTR-EGFP reporter and siRNAs against lamin a/c (L), gfp (G), pkr (P), or rha (R), to measure the effect of PKR on
RHA-mediated LTR-transactivation. Cell lystates were collected and assayed at three time points (24, 48, and 72 hours). Each value is the average of
three independent measures, and the error bars represent the standard deviations. Fluorescence measures were corrected to a constitutive bactin-
renilla reporter, then normalized to the Lamin a/c siRNA treatment. (B) Western blots of electrophoretically separated proteins, from HEK293T cells
treated as in (A). Proteins were detected with antibodies to GFP, GAPDH, PKR, and RHA to show intended depression of targeted proteins and PKR-
dependent control of RHA-mediated LTR-transactivation. (C) A bar graph representing the total relative fluorescence levels in HEK293T cells alone
(NR), or transiently transfected with a HIV-1 LTR-EGFP reporter (C), and with wild-type PKR (PKR-WT), a kinase inactive mutant (PKR-K296R) or a
mutant that does not regulate translation via eIF2a (PKR-T487A), at three concentrations (10, 20, and 40 ng/well) to show kinase activity is required to
regulate RHA-mediated induction of the HIV-1-LTR promoter sequence. Fluorescence levels are not normalized against a constitutive bactin reporter.
Each value is the average of three independent measures, and the error bars represent the standard deviations. (D) The relative fluorescence levels in
HEK293T cells transfected with the HIV-1 LTR-EGFP reporter and a kinase inactive mutant (PKR-K296R), or a translational control mutant (PKR-T487A)
from (C) normalized against a constitutive bactin reporter to show specific, dose-dependent PKR-regulated inhibition of the RHA activity. A t-test was
performed on the data to establish the statistical significance of the observed PKR-mediated reduction in the LTR reporter.
doi:10.1371/journal.ppat.1000311.g005
Regulation of RHA by PKR
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Discussion
The innate immune response is the primary shield against
microbial infection and directs the subsequent adaptive response.
The protein kinase PKR was identified some 30 years ago as a
sentinel kinase that is constitutively expressed in all cells as a
monomer that subsequently dimerizes to form the active enzyme.
We show here that RHA is a novel substrate for PKR and explore
points of significance that arise from the finding.
PKR’s interaction with RHA identifies a novel mechanism by
which the previously established translational regulator can also
modulate transcription. This function of PKR identifies an
antiviral pathway that represents a plausible target for treatment
of established retroviral infections. Consistent with this antiviral
mechanism, RHA is positively associated with viral replication.
RHA transactivates the Bovine Viral Diarrhea virus by binding to
the terminal nontranslated regions of the viral RNA genome [26].
RHA also positively regulates expression of the HIV-1 transactiva-
tion response region [27] (and in this study). In addition, RHA
mediates release of retroviral transcripts from the splicesome and
transports the RNA from the nucleus. Correspondingly, the
helicase has been shown to associate with the constitutive transport
element (CTE) of type D-retroviruses and Rev Response elements
of HIV-1 and to associate with cellular mRNA export receptors
TAP, SAM68, and HAP95 [28,29]. Of particular relevance to this
study, RHA also associates with the HIV-1 gag protein and
becomes incorporated into the HIV-1 particle [25]. Our data
demonstrates that coexpression of HIV-1 provirus with RHA
peptides that are substrates for PKR subsequently enhances viral
infectivity. Significantly, the truncated RHA peptides do not
encode any helicase activity and are therefore incapable of
transactivating the HIV-1 LTR sequences. Appropriately, no
benefit to virus replication was observed by co-expressing RHA
peptides. We contend the observed increased infectivity, without
increased replication, is due to inhibition of the ensuing antiviral
response mediated by PKR, through the interaction between
RHAs second RBM and PKR. Therefore an additional function
of RHA possibly exploited by HIV-1 is to dampen the primary
host immune response. Such a role adds weight to the previous
observed incorporation of RHA into the virion.
RHA was initially identified as a homolog of the Drosophila
melanogaster maleless gene that regulates chromosomal dosage
compensation, a function essential for survival of male larvae
[30]. Deletion of rha-1 in Caenorhabditis elegans indicates that the
helicase controls germ cell proliferation and development [31].
Embryonic lethality of rha null mice at day 11 of gestation shows
that the helicase is also essential for development in mammals
[32]. Several lines of evidence suggest that RHA may also have a
role in the immune response. The helicase appears as an auto-
antigen in the auto-immune disease systemic lupus erythematosus
[33]. In addition, RHA associates with the transcription cofactor
and histone acetyltransferase CBP, and the transcription factor
NFkB, both potent factors in immune responses [34,35].
Furthermore, the rha gene promoter contains regulatory elements
that control induction of this constitutively expressed protein
during cellular immune responses, including an Interferon
Stimulatory Response Element. Interestingly, immunohistochem-
istry of IFNa-treated cells shows accumulation of the helicase
within promyelocytic leukemia nuclear bodies that are involved in
transcription of IFN-induced genes [35]. Accordingly, RHA may
not only be induced by IFN, but could also regulate its
downstream effects. Therefore appropriation of RHA by viruses
during their replication would not only boost viral transcripts, but
may also blunt the innate immune response.
Figure 6. The RBD of RHA enhances HIV-1 infectivity. (A) The
graph shows RHA-regulated, LTR-expression is increased in HEK293T
cells in proportion to increasing amounts of the N-terminal RHA RBM.
Values are normalized to equivalent levels of an empty control plasmid.
Error bars represent standard deviations. (B) The effect of different RHA
constructs on HIV-1 infectivity was assessed using recombinant virus in
the T-cell line MT-2. Values were normalized to HIV-1 produced with an
empty control vector. Each value is the average of three independent
experiments with replicates. The error bars represent the standard
deviations. (C) A bar graph representing the relative replication capacity
of HIV-1 produced with different RHA or control constructs (RBD, RBM1,
and RBM2). Viral replication is measured by assaying reverse
transcriptase activity. The values shown are an average of four
replicates. Error bars show the standard deviation.
doi:10.1371/journal.ppat.1000311.g006
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Our observations of interplay between RHA and PKR
strengthen the perspective that helicases are key signaling
molecules. Helicases had been thought of as terminal proteins in
signal cascades that elicit appropriate responses by remodeling
RNA and DNA. The data here underpin previous findings with
RIG-I and IFIH-I to support a primary role for helicases as
immediate players in the innate immune response [36]. We
demonstrate that just as the CARD domains of these helicases and
their associated adaptor molecules mediate signal transduction, the
RBM of RHA mediates the association with PKR. Importantly, by
identifying an inhibitory effect of phosphorylation on the function
of RHA, we present compelling evidence of this association, with
resulting effect upon the enzyme’s function. Correspondingly,
peptides within RHA’s RBD, that interacts with PKR, enhance
the infectivity of HIV-1. The data support a paradigm by which
the function of a class of RNA-responsive proteins are coordinated
or exacerbated by interaction via their RBMs. The consequence of
this could be considerable, as at least 17 human proteins have been
described that encode RBMs. Moreover, gene deletion studies
highlight the importance of these proteins. Disruption of the
RBM-containing ribonuclease Dicer, TARBP, the adenosine
deaminase ADAR-1, and, as discussed, RHA, is embryonically
lethal in murine models [32,37–39]. Similarly, mice null for the
PKR-activator PACT, spermatid perinuclear RNA-binding pro-
tein (STRBP), and the testis-specific mRNA editor TENR, which
all encode RBMs, have retarded growth, increased mortality and/
or reduced fertility (G.C. Sen, unpublished results; L. Saunders
and G.N. Barber, unpublished results; [40–42]. PKR has
previously been reported to associate with four members of this
family of proteins. As mentioned the kinase is activated by PACT,
and conversely inhibited by TARBP, in addition to the nuclear
factor of activated T-cells, NF90, as well as the antiviral protein
ADAR1 [43,44]. The association here between PKR and RHA
via their RBMs strengthens an emerging paradigm whereby this
motif acts as a signaling domain to coordinate the dsRNA-
response as has been identified for the CARD domains of the
cytoplasmic helicases RIG-I and IFIH-I, or the TIR domains of
TLRs and their adaptor molecules.
Materials and Methods
Plasmids and Reagents
Full-length RHA and truncated GST-RHA fusion plasmids
were constructed as described by Nakajima et al. [34]. RHA was
expressed for protein purification as a recombinant baculovirus as
described by Lee et al. [30]. Wild-type PKR was expressed as
described previously by Gabel et al. [16]. Truncated RHA
constructs, encoding the N-terminal 262 amino acid (pRHARBD),
the first 76 amino acids (pRHARBM1), or residues 169 to 262
(pRHARBM2), were generated in pCMVFlag (Sigma). Other
plasmid constructs were gifted by others as listed in the
acknowledgments.
Gene silencing was achieved though RNA interference using the
chemically synthesized siRNAs, AAAUUUUCUGUAUGC-
CUGG, CAGCCAAAUUAGCUGUUGA, AATGTTCTTCTG-
GAAGTCCAG, and GCUGACCCUGAAGUUCAUCUU, tar-
geting rha, pkr, lamin A/C, and egfp transcripts (Dharmacon). All other
reagents were purchased from Sigma unless otherwise indicated.
Cell Culture and Treatments
Adherent cells were maintained in DMEM, while suspension
cells were cultured in RPMI supplemented with 10% fetal bovine
serum and cells were grown at 37uC with a humidified 95% air,
5% CO2 atmosphere. Murine (C57/BL6) PKR null MEFs were
transformed with the pBeloBAC construct encoding an approx-
imately 60 kbp genomic fragment that encompassed the gene and
promoter elements of human pkr as described previously [45,46].
Reporter assays were performed in HEK293T cells at 20–60%
confluency in 6-well dishes (Falcon). Cells were transfected using
the calcium phosphate method with 300 ng pLTR-EGFP, 2 ng
pSV2tat72, 10 ng of a control reporter pbactin-RL and 4 nM
siRNA per well. Cells were collected 24, 48, and 72 hours after
transfection, Assays to measure the effect of the pRHARBD were
performed in HEK293T cells cultured in 24 well dishes transfected
with 50 ng of pLTR-EGFP, 10 ng pbactin-RL and 0, 10, 20, 40,
80, 160, or 640 ng of either pRHARBD or pCMVFlag DNA. The
cells were cultured for 62 hours. HEK293T cells were washed
with phosphate-buffered saline (PBS), and lysed in Promega’s
passive lysis buffer for fluorescence and luciferase measurements
using a Wallac Victor3 plate reader (Perkin-Elmer). Fluorescence
values were normalized to the total protein level quantified using
the Bradford assay (BioRad) and also compared to an internal
reporter quantified by Renilla luciferase assay (Promega). All
experiments were performed in triplicate and independently
replicated a minimum of three times.
PKR was activated in MEFs by adding 100 mg/ml pIC to the
culture supernatant for 2 hours. Alternatively, THP-1 cells were
treated with 10 mg/ml E. coli LPS for 2 hours as described by
Gusella et al. [47]. Finally, HEK293T transfected with pcDNA-
PACT/DPACT were temporally treated with Actinomycin-D as
described by Peters et al. [20].
Virus Production and Infection
HIV-1 particles were produced by polyethylenimine transfec-
tion of HEK293T cells with 5 mg of pNL4-3-Luc-RE proviral
DNA, 2.5 mg of pNLA1, and 2 mg of each RHA construct
(pRHARBD, pRHARBM1, or pRHARBM2). Viral particles were
harvest after 36 hours, purified from the supernatant and
concentrated by ultracentrifugation through 20% sucrose, using
ultracentrifuge at 87,0006g for 1 hour at 4uC in a Beckman
centrifuge, and virus pellets were eluted in PBS, and quantitated
with the HIV-1 Antigen p24-CA MicroELISA Vironostika system
(Organon Teknika). Equivalent amounts of virus were used to
infect 16106 MT-2 cells maintained in RF10 (Gibco/BRL),
supplemented with 2 mM L-glutamine and 24 mg/ml gentamicin
for 2 hours at 37uC. Residual virus was removed by washing with
PBS and cells were resuspended in RF10, then cultured at 37uC
for 48 hours, before washing with PBS and harvesting in Cell
Culture Lysis Reagent (Promega). The success of a single round of
infection was determined by the level of luciferase activity,
measured by luciferase assay (Promega) using a Fluorostar plate
reader (BMG). HIV-1 infectivity was assessed in three independent
experiments with two or four replicates at each occasion.
Reverse Transcriptase Activity Assay
Ten ml of non-concentrated viral supernatant was mixed with
10 mL of 0.3% NP40, followed by addition of 40 mL reverse
transcriptase (RT) reaction cocktail containing 5 mg/ml of the
template primer poly(rA)-(dT)15 (Amersham Pharmacia Biotech),
in 50 mM Tris-HCl (pH 7.8), 2 mM DTT, 5 mM MgCl2,
7.5 mM KCl, and 0.5 mCi a33P-dTTP. Following incubation
for 2 hours at 37uC, 8 mL of the reaction mixture was spotted onto
DEAE81 ion-exchange paper (Whatman) and washed six times in
300 mM NaCl and 30 mM sodium citrate to remove unincorpo-
rated a33P-dTTP. RT activity was determined by the level of
a33P-dTTP using a Wallac 1450 Microbeta-Plus liquid scintilla-
tion counter (Perkin-Elmer).
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Immune Analysis
Human PKR was immunoprecipitated using the mouse
monoclonal antibody 71/10 [48]. PKR was detected in Western
blot with multiple redundant antibodies, including a rabbit
monoclonal antibody YE350 from Abcam (for human PKR), and
rabbit polyclonal antibodies D20, and B10 from Santa Cruz
Biotechnology. Activation of PKR in vivo was confirmed by
detecting phosphorylation of eIF2a using a rabbit anti-phospho-
eIF2a (Ser51) antibody from Stressgen. GAPDH and GFP were
detected in Western blots using mouse monoclonal antibodies from
Chemicon and Roche, respectively. Endogenous RHAwas detected
in Western blot analysis and immunoprecipitated from whole-cell
lysates using a rabbit polyclonal antibody [30], a rabbit polyclonal
antibody ab26271, and a mouse monoclonal ab54593 from Abcam.
Recombinant HA-tagged RHA was immunoprecipitated and
detected in Western blots using the monoclonal antibody HA.11
from Covance. Phosphorylated amino acids were detected using
rabbit polyclonal anti-phosphoserine, and mouse monoclonal anti-
phosphothreonine antibodies from Zymed Laboratories (Invitro-
gen). Cells were collected in lysis buffer (50 mM Tris-HCL
[pH 7.4], 150 mM NaCl, 50 mM NaF, 10 mM b-glycerophos-
phate, 0.1 mM EDTA, 10% glycerol, 1% Triton X-100, and
protease inhibitors). Immune complexes were resuspended in
loading buffer (125 mM Tris-HCl [pH 6.8], 4% SDS, 20%
glycerol, 10% b-mercaptoethanol, 1% Bromophenol Blue) for
separation by SDS-polyacrylamide electrophoresis (SDS-PAGE).
Separated proteins were visualized by staining with BioRads
Coomassie, or Silver Stain Plus reagents. Stained protein bands
were excised from the gel and analyzed by Maldi-ToF. Alterna-
tively, separated proteins were electrophoretically transferred to
either Immobilon-P, or Immobilon-FL membrane (Millipore) for
immunoblotting using horseradish peroxidase-linked secondary
antibody and ECL from Amersham, or fluorescently labeled (680
and 800 nm) secondary antibodies (Invitrogen, Molecular Probes),
respectively. Fluorescently labeled antibodies were detected and
quantitation using the Odyssey infrared imaging system (Li-Cor).
Replicate experiments to quantitate RHA phosphorylated by PKR
in vivo recorded mean values of phosphorylated residues on RHA
coimmunoprecipitated with PKR of 1.6+/20.9 for phosphoserine
and 5.7+/21.3 for phosphothreonine. No phosphorylated residues
were detected with these phospho-specific antibodies in RHA
directly immunoprecipitated. The values of total RHA coimmuno-
precipitated with the anti-PKR antibody were 55.3+/25.8, while
that directly immunoprecipitated with the anti-RHA antibody was
111.5+/213.2 in this experiment.
Protein Purification and Interaction Assays
GST and His-tagged proteins were purified from E. coli and Sf-9
insect cells on either glutatione-Sepharose 4B beads (Amersham)
or Ni-NTA agarose (Qiagen) according to the manufacturer’s
protocols. To map protein interactions, PKR was synthesized in
an in vitro coupled transcription–translation system (Promega)
with 35S-methionine (NEN-DuPont), then incubated in cleared E.
coli lysate with protease inhibitors with GST-fused RHA constructs
for 2 hours at 4uC. Supernatant, containing unbound proteins,
was removed after 5006g centrifugation. Recovered beads were
rinsed five times with bead-binding buffer (50 mM K3PO4
[pH 7.5], 150 mM KCl, 1 mM MgCl2, 10% glycerol, 1% Triton
X-100 and protease inhibitors). The resin-bound proteins were
eluted with loading buffer and separated by SDS-PAGE, then
visualized by autoradiography.
The experiment on the effect of RNA on the interaction between
PKR and the 263 amino acid GSTRHA-fusion peptide was
conducted as above with an additional step. Approximately 20 mg of
the GSTRHA peptide was incubated with a 16 bp dsRNA at 10,
100, or 1000-fold excess for one hour prior to addition of 35S-
labeled PKR. The 16 bp dsRNA was synthesized in vitro using T7
RNA polymerase then gel purified from an SDS-PAGE gel.
To measure the relative affinity of unphosphorylated or
phosphorylated RHA for RNA, the 263 amino acid N-terminus
of RHA was synthesized in vitro with either 35S-methionine during
the synthesis reaction or c32P-ATP in a PKR kinase assay. Labeled
proteins were incubated in binding buffer (20 mM Tris-HCL
[pH 7.4], 200 mM NaCl, and 5 mM DTT) with pIC conjugated
to agarose beads (Promega) for an hour, then washed with binding
buffer five times, eluted with loading buffer and separated by SDS-
PAGE. Recovered proteins were detected by exposure to a
phosphor screen, imaged with a Storm-840 scanner, and
quantified with ImageQuant software (Molecular Dynamics).
Phosphorylation Analysis
For kinase assays, full-length RHA, truncated GSTRHA fusion
proteins, and the PKR substrate B56a [49] were incubated with
recombinant PKR in 30 ml DBGA buffer (10 mM Tris-HCl
[pH 7.6], 50 mM KCl, 2 mM [CH3COO]2Mg4H2O, 7 mM b-
mercaptoethanol, 20% glycerol), 20 ml of DBGB buffer (2.5 mM
MnCl2 in DBGA), 5 ml of ATP mixture (10 mM ATP and 1.5 mCi
of c32P-ATP/ml), and 5 ml of pIC (12 ng/ml) at 30uC for
10 minutes. Phosphorylated proteins were denatured in loading
buffer and separated by SDS-PAGE, then visualized by autora-
diography. The levels of total proteins in the SDS-PAGE gel were
visualized by staining with Coomassie blue. In vivo phosphoryla-
tion of RHA was detected as described above (Immune analysis).
Mass Spectrophotometry
Protein were excised from SDS-PAGE gels and washed in 50%
ethanol, 5% acetic acid, reduced and alkylated with DTT and
iodoacetamide. The gel slices were dehydrated in acetonitrile and
dried in a speed-vac, then digested in 20 ng/ml Trypsin in 50 nM
ammonium bicarbonate overnight at room temperature. Released
peptides were extracted from the polyacrylamidewith 50%acetonitrile
with 5% formic acid. The extract was evaporated for LC-MS analysis
using a Finnigan LTQ linear ion trap mass spectrometer. Two ml
volumes of the extract were injected and the peptides eluted from the
column by acetonitrile in a 50 mMacetic acid gradient at a flow rate of
0.2 ml/minute. The microelectrospray ion source was operated at
2.5 kV. Samples were also analyzed by Maldi-ToF. Data collected in
the experiment was used to search the NCBI non-redundant database
with the search program TurboSequest.
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